Medicinova (MNOV) Receivables (2013 - 2025)

Medicinova's (MNOV) quarterly Receivables came in at $134599.0 in Q2 2025, down 86.54% on a QoQ basis from $1.0 million in Q3 2023.

Medicinova (MNOV) Receivables (2013 - 2025) Analysis & Trends

Medicinova (MNOV) has 6 years of Receivables data on file, last reported at $134599.0 in Q2 2025.

On a quarterly basis, Receivables changed N/A year-over-year to $134599.0 in Q2 2025; TTM through Jun 2025 was $134599.0, a N/A change from a year earlier, with the FY2015 full-year figure at $6.0 million, changed 0.0% from the prior year.
Receivables for Q2 2025 stood at $134599.0, down from $1.0 million in the prior quarter.
Over the last five years, Receivables for MNOV reached as high as $4.0 million in Q1 2021 and fell as low as $134599.0 in Q2 2025.
Historically, Receivables has averaged $1.7 million across 3 years, with a median of $1.0 million in 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	4.97 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	938.02 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	1.13 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Medicinova	64.48 Mn	64.48 Mn	4,754.00	-

Download Data